当前位置:首页 >英文主页 >中英对照 > 报告详情

英国下议院图书馆:2025英格兰减肥药物状况研究报告(英文版)(67页).pdf

上传人: Y**** 编号:709960 2025-05-26 67页 808.53KB

下载:

1、 commonslibrary.parliament.uk Research Briefing 10 April 2025 By Bukky Balogun Weight loss medicines in England 1 NHS weight loss treatment and services in England 2 GLP-1 medicines 3 Making new medicines available in the NHS in England 4 NICEs draft guidance(June 2024)for the rollout of tirzepatide

2、(Mounjaro)on the NHS 5 NICEs final guidance(December 2024)for the rollout of tirzepatide(Mounjaro)on the NHS 6 New clinical research into obesity 7 Concerns about weight loss medicines Weight loss medicines in England 2 Commons Library Research Briefing,10 April 2025 Number 10171 Contributing Author

3、s Image Credits Adobe Stock image 853953784 Insulin injection pen by Kassandra Adobe Stock(https:/ Stock License 2024 Adobe/image cropped.Disclaimer The Commons Library does not intend the information in our research publications and briefings to address the specific circumstances of any particular

4、individual.We have published it to support the work of MPs.You should not rely upon it as legal or professional advice,or as a substitute for it.We do not accept any liability whatsoever for any errors,omissions or misstatements contained herein.You should consult a suitably qualified professional i

5、f you require specific advice or information.Read our briefing Legal help:where to go and how to pay for further information about sources of legal advice and help.This information is provided subject to the conditions of the Open Parliament Licence.Sources and subscriptions for MPs and staff We try

6、 to use sources in our research that everyone can access,but sometimes only information that exists behind a paywall or via a subscription is available.We provide access to many online subscriptions to MPs and parliamentary staff,please contact hoclibraryonlineparliament.uk or visit commonslibrary.p

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要讨论了英格兰国家医疗服务系统(NHS)对减肥药物的提供情况。主要内容包括: 1. NHS在英格兰提供的减肥治疗和服务,包括不同层级的体重管理服务,以及NHS英格兰的试点计划。 2. 胰高血糖素样肽-1(GLP-1)类药物,包括Mounjaro(tirzepatide)和Ozempic、Wegovy和Rybelsus(semaglutide),以及它们在英格兰的使用情况。 3. 在NHS英格兰中引入新药物的过程,包括产品许可、NICE的价值评估,以及NHS英格兰对新药物资金要求的变更请求。 4. NICE关于在NHS中推广tirzepatide(Mounjaro)的草案和最终指导,包括NHS英格兰对推广周期的估计和提议。 5. 新的肥胖临床研究,以及关于减肥药物的担忧,包括在线私人提供者的使用、不当处方、监管收紧、获取医疗记录、非法供应、安全使用在线药物的指导、副作用和药物短缺。
英国NHS如何提供减肥治疗? GLP-1类药物如何帮助减肥? NHS如何为新型减肥药提供资金?
客服
商务合作
小程序
服务号
折叠